新型双能CT融合技术对肝癌TACE术后的评估

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To evaluate the application value of a new modified dual energy image fusion in hepatocellular carcinoma after transcatheter arterial chemoembolization(TACE). Method: Twenty-six hepatocellular carcinoma(HCC) patients after post-TACE underwent normal and three phases dual-energy CT scanning(non-enhanced, arterial, portal, and delayed phases scanning) were enrolled. The arterial phase scans used the dual-energy mode. Two image sets were used to process the data: A, the weighted average image was automatically generated from a linear blending of the data. B, the new double energy fusion was obtained. DSA regarded as the gold standard, we evaluated the feasibility of two image sets, which discriminate contrast enhanced lesions from compact iodized oil accumulations, thereby helping to identify viable lesions around the HCC previously-treated by TACE. Result: DSA revealed 60 lesions in 26 patients, and 45 of them had clear tumor vessel and supply blood. The sensitivity of B(93.3%) was higher than that of A(71.1%)(χ2=8.1, P=0.004), while the specificity of B(93.3%) was insignificantly different with A(66.7%)(χ2=1.5, P=0.221). The B set has a better consistency of DSA(K=0.83, P=0.000). Conclusion: After HCCs with TACE, displaying of iodized oil accumulations and/or enhanced lesion in outside is much better in the new double energy fusion than that in conventional CT protocol.

Key words： Liver neoplasms Tomography, X-ray computed

Received: 16 December 2015

PACS:	Ｒ735.7
	Ｒ814.42

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Da-fu
	LI Zhen-hui
	YANG Guang-jun
	WANG Guan-shun
	LIAO Cheng-de
	DING Ying-ying

Cite this article:

ZHANG Da-fu,LI Zhen-hui,YANG Guang-jun, et al. Evaluation of hepatocellular carcinoma after TACE by using new dual energy image fusion technique[J]. JOURNAL OF CHINA MEDICAL IMAGING, 2016, 27(8): 557-561.

URL:

http://www.jccmi.com.cn/EN/ OR http://www.jccmi.com.cn/EN/Y2016/V27/I8/557

[1]Dong S, Ye X, Yuan Z, et al. Relationship of apparent diffusion coefficient to survival for patients with unresectable primary hepatocellular carcinoma after chemoembolization[J]. Eur J Radiol, 2012, 81(3): 472-477.
[2]Lencioni R. Chemoembolization for hepatocellular carcinoma[J]. Semin Oncol, 2012, 39(4): 503-509.
[3]Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective[J]. Jpn J Clin Oncol, 2012, 42(4): 247-255.
[4]Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma[J]. AJR, 2000, 175(3): 699-704.
[5]Graser A, Johnson TR, Chandarana H, et al. Dual energy CT: preliminary observations and potential clinical applications in the abdomen[J]. Eur Radiol, 2009, 19(1): 13-23.
[6]Johnson TR, Krauss B, Sedlmair M, et al. Material differentiation by dual energy CT: initial experience[J]. Eur Radiol, 2007, 17(6): 1510-1517.
[7]Kalender WA, Perman W, Vetter J, et al. Evaluation of a prototype dual-energy computed tomographic apparatus. Ⅰ. Phantom studies[J]. Med Phys, 1986, 13(3): 334-339.
[8]Shim JH, Lee HC, Kim S, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models[J]. Radiology, 2012, 262(2): 708-718.
[9]Simons D, Kachelriess M, Schlemmer HP. Recent developments of dual-energy CT in oncology[J]. Eur Radiol, 2014, 24(4): 930-939.
[10]Agrawal MD, Pinho DF, Kulkarni NM, et al. Oncologic applications of dual-energy CT in the abdomen[J]. Radiographics, 2014, 34(3): 589-612.
[11]卫生部. 原发性肝癌诊疗规范（2011年版）[J]. 临床肿瘤学杂志，2011，16（10）：929-946.
[12]Barone M, Ettorre GC, Ladisa R, et al. Transcatheter arterial chemoembolization(TACE) in treatment of hepatocellular carcinoma[J]. Hepatogastroenterology, 2002, 50(49): 183-187.
[13]Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver[J]. J Hepatol, 2001, 35(3): 421-430.
[14]Asayama Y, Yoshimitsu K, Nishihara Y, et al. Arterial blood supply of hepatocellular carcinoma and histologic grading: radiologic-pathologic correlation[J]. AJR, 2008, 190(1): 28-34.
[15]Kim H, Kim AY, Han JK, et al. Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images[J]. Radiology, 2002, 225(3): 773-780.
[16]Kim SH, Lee WJ, Lim HK, et al. Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: usefulness of attenuation value measurement at quadruple-phase helical computed tomography[J]. J Comput Assist Tomogr, 2007, 31(2): 198-203.
[17]Choi BI, Kim HC, Han JK, et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings[J]. Radiology, 1992, 182(3): 709-713.
[18]Lee J, Jeong WK, Kim Y, et al. Dual-energy CT to detect recurrent HCC after TACE: initial experience of color-coded iodine CT imaging[J]. Eur J Radiol, 2013, 82(4): 569-576.